JDRF welcomes Disability Advisory Committee's recommendation that all Canadians needing life-sustaining therapy should automatically meet the criteria for the Disability Tax Credit and urges the Government to adopt this approach
JDRF Canada, the leading global funder of type 1 diabetes (T1D) research, welcomes the release of the Disability Advisory Committee’s (DAC) Firs...Read More
JDRF showcases the remarkable people who benefit from JDRF-funded research while striving to accelerate the pace of research in Canada.
JDRF and the American Diabetes Association, in Collaboration with Multiple Diabetes Organizations Publish New Classification and Staging Approach for Presymptomatic Type 1. Diabetes Organizations Endorse Concept that Autoimmune Disease Begins Long Before Symptoms Occur and Progresses through Distinc...
The stationary bicycles are tuned, greased and ready for corporate Canada to start cycling in support of JDRF at the 2015 JDRF Ride for Diabetes Research (JDRF Ride). This fall, all across Canada various business sectors will trade in their suits for sweats as they go head-to-head in this unique sta...
A Canadian research team working on the development of an external artificial pancreas is receiving a grant of $2,509,367 USD from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the U.S. National Institutes of Health (NIH).
ViaCyte, Inc. announced the opening of a second site in its Phase 1/2 trial called STEP ONE, or Safety, Tolerability and Efficacy of VC-01™ Combination Product in Type One Diabetes (T1D), at the University of Alberta Hospital in Edmonton, Alberta funded in part by the JDRF Canadian Clinical Tr...
Innovative treatment for type 1 diabetes marks first step towards vision of regional network for islet cell isolation and transplant
Two-year $300 Million Extension of the Special Diabetes Program Allows for the Continuation of Promising Ongoing Clinical Trials
The U.S. Senate overwhelmingly approved legislation last night for a two-year extension of the Special Diabetes Program (SDP)—an initiative that accounts for roughly one-third of all Federally-funded type 1 diabetes (T1D) research in the United States. The decision comes on the heels of the st...
JDRF-Supported Researchers Make Gains in Designing Islet Cell Encapsulation Materials for Use in Type 1 Diabetes Therapies
New study shows size and shape of encapsulation materials have an effect on islet cell survival
BD and Medtronic Collaborate to Introduce a New Infusion Set with BD FlowSmart Technology Designed to Improve Insulin Pump Therapy
BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Medtronic (NYSE: MDT) today announced a collaboration to introduce a new insulin pump infusion set with BD FlowSmart™ technology
BD Receives FDA Clearance for a Novel Infusion Set with BD FlowSmart Technology to Enhance the Use of Insulin Pumps
BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for a new insulin infusion set with BD FlowSmartTM technology.